TaiMed Biologics Inc (TMB, 中裕新藥) shares surged in Taipei yesterday after the company said its HIV/AIDS drug obtained a green light from the US Food and Drug Administration (FDA).
The stock shot up 10 percent to its daily limit of NT$234 shortly after opening, and remained at its peak throughout the session, outperforming the TAIEX, which fell 0.36 percent to 10,745.32 points.
The drug, marketed as Trogarzo (ibalizumab-uiyk), is a new antiretroviral for adults with HIV who have developed a resistance to other drugs, the company said.
Trogarzo is the first drug in a new class of antiretroviral medications that can significantly benefit a small percentage of patients who have run out of HIV treatment options, said Jeff Murray, deputy director of the Division of Antiviral Products at the FDA’s Center for Drug Evaluation.
Its introduction could improve the outcome for patients who are at high risk of potentially fatal HIV-related complications, he said in a statement.
In a study of 40 extremely treatment-experienced patients with multidrug resistance HIV-1, who continued to have a high virus load after being treated with 10 or more antiretrovirals, 43 percent achieved HIV RNA suppression, the FDA said.
Among the 292 patients who participated in Trogarzo studies, the most common adverse reactions were diarrhea, dizziness, nausea and rashes, with more severe side effects limited to severe rashes and immune reconstitution syndrome, the FDA said.
Trogarzo is administered intravenously once every 14 days in combination with other antiretrovirals, TaiMed said in a filing with the Taiwan Stock Exchange, adding that the wholesale price is US$118,000 per year.
The firm, which in May last year submitted a biologics license application to market the drug, said that the FDA had granted priority review, as well as orphan-drug and breakthrough-therapy designations, to help speed up the approval process.
TaiMed said it is in the process of designing a phase III clinical trial for an intramuscular injection formulation of Trogarzo.
In anticipation of the drug’s launch in the US, the company has increased its budget by NT$130 million (US$4.44 million) to build a new protein drug manufacturing plant, pushing total spending to NT$1 billion, a separate filing said.
Taiwan’s technology protection rules prohibits Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) from producing 2-nanometer chips abroad, so the company must keep its most cutting-edge technology at home, Minister of Economic Affairs J.W. Kuo (郭智輝) said yesterday. Kuo made the remarks in response to concerns that TSMC might be forced to produce advanced 2-nanometer chips at its fabs in Arizona ahead of schedule after former US president Donald Trump was re-elected as the next US president on Tuesday. “Since Taiwan has related regulations to protect its own technologies, TSMC cannot produce 2-nanometer chips overseas currently,” Kuo said at a meeting of the legislature’s
GEOPOLITICAL ISSUES? The economics ministry said that political factors should not affect supply chains linking global satellite firms and Taiwanese manufacturers Elon Musk’s Space Exploration Technologies Corp (SpaceX) asked Taiwanese suppliers to transfer manufacturing out of Taiwan, leading to some relocating portions of their supply chain, according to sources employed by and close to the equipment makers and corporate documents. A source at a company that is one of the numerous subcontractors that provide components for SpaceX’s Starlink satellite Internet products said that SpaceX asked their manufacturers to produce outside of Taiwan because of geopolitical risks, pushing at least one to move production to Vietnam. A second source who collaborates with Taiwanese satellite component makers in the nation said that suppliers were directly
Top Taiwanese officials yesterday moved to ease concern about the potential fallout of Donald Trump’s return to the White House, making a case that the technology restrictions promised by the former US president against China would outweigh the risks to the island. The prospect of Trump’s victory in this week’s election is a worry for Taipei given the Republican nominee in the past cast doubt over the US commitment to defend it from Beijing. But other policies championed by Trump toward China hold some appeal for Taiwan. National Development Council Minister Paul Liu (劉鏡清) described the proposed technology curbs as potentially having
TECH WAR CONTINUES: The suspension of TSMC AI chips and GPUs would be a heavy blow to China’s chip designers and would affect its competitive edge Taiwan Semiconductor Manufacturing Co (TSMC, 台積電), the world’s biggest contract chipmaker, is reportedly to halt supply of artificial intelligence (AI) chips and graphics processing units (GPUs) made on 7-nanometer or more advanced process technologies from next week in order to comply with US Department of Commerce rules. TSMC has sent e-mails to its Chinese AI customers, informing them about the suspension starting on Monday, Chinese online news outlet Ijiwei.com (愛集微) reported yesterday. The US Department of Commerce has not formally unveiled further semiconductor measures against China yet. “TSMC does not comment on market rumors. TSMC is a law-abiding company and we are